SAB Biotherapeutics Inc Financial Flexibility Index
SAB Biotherapeutics Inc financial flexibility index. SAB Biotherapeutics Inc (SABS) has a Financial Flexibility Index of -0.92x as of June 2026. Free cash flow of $-21.54 Million (operating CF $-24.11 Million minus capex $2.57 Million) represents -1% of total liabilities ($23.43 Million). See SAB Biotherapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of SAB Biotherapeutics Inc (2019–2025)
Financial flexibility index of SAB Biotherapeutics Inc from 2019 to 2025. Historical Financial Flexibility Index trend for SAB Biotherapeutics Inc across 7 annual periods. Check SAB Biotherapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
SAB Biotherapeutics Inc Financial Flexibility Index by Year (2019–2025)
SAB Biotherapeutics Inc financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for SAB Biotherapeutics Inc. For the full cash flow conversion analysis, see SAB Biotherapeutics Inc (SABS) cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.06x | $-43.84 Million | $-44.78 Million | $21.32 Million | ▼ -10.4% |
| 2024 | -1.86x | $-33.95 Million | $-34.29 Million | $18.23 Million | ▼ -99.2% |
| 2023 | -0.94x | $-24.92 Million | $-25.12 Million | $26.64 Million | ▲ +12.8% |
| 2022 | -1.07x | $-21.29 Million | $-23.46 Million | $19.85 Million | ▼ -453.4% |
| 2021 | 0.30x | $12.93 Million | $1.99 Million | $42.59 Million | ▼ -76.6% |
| 2020 | 1.30x | $22.74 Million | $10.00 Million | $17.53 Million | ▲ +406.1% |
| 2019 | -0.42x | $-8.61 Million | $-9.21 Million | $20.31 Million | — |